Genetic changes in prostate cancer

Pathology International

Volumn 47, Issue 11, 1997, Pages 735-747

  Konishi, Noboru ^a   Cho, Masaki ^a   Yamamoto, Kunichika ^a   Hiasa, Yoshio ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Chromosome; Gene; Genome; Mutation; Prostate cancer

Indexed keywords

DNA; PROTEIN P53; RETINOBLASTOMA PROTEIN;

CELL CYCLE; CHROMOSOME ABERRATION; DNA HYBRIDIZATION; DNA METHYLATION; GENE ACTIVATION; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0030720838     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1827.1997.tb04451.x     Document Type: Review

References (117)

1. Chiaroda A. National Cancer Institute roundtable on prostate cancer: Future research directions. Cancer Res. 1991; 51: 2498-2505.
2. Tominaga Y, Aoki K, Hanai A, Kunihara N, eds. Cancer Statistics In Japan: Incidence/Mortality/Prognosis. Shinohara Shuppan, Tokyo, 1993.
3. Muir C, Waterhouse J, Mack T, Powell J, Whelan S. Cancer Incidence In Five Countries, Vol. V, No. 88. IARC Sci. Publ., Lyon, 1987.
4. Akazaki K, Stemmerman GN. Comparative study of latent carcinoma of the prostate among Japanese in Japan and Hawaii. J Natl Cancer Inst. 1973; 50: 1137-1144.
5. Yatani R, Shiraishi T, Nakakuki K et al. Trends in frequency of latent prostate carcinoma in Japan from 1965-1979 to 1982-1986. J. Natl Cancer Inst. 1988; 80: 683-687.
6. Tilley WD, Wilson CM, Marcelli M, McPhaul MJ. Androgen receptor gene expression in human prostate carcinoma cell line. Cancer Res. 1990; 50: 5382-5386.
7. Fan K, Peng C-F. Predicting the probability of bone metastasis through histological grading of prostate carcinoma: A retrospective correlative analysis of 81 autopsy cases with antemortem transurethral resection specimen. J. Urol. 1983; 130: 708-711.
8. Isaacs WB, Bova GS, Morton RA, Bussemakers MJG, Brooks JD, Ewing CM. Molecular genetics and chromosomal alterations in prostate cancer. Cancer 1995; 75: 2004-2012.
9. McNeal JE, Bostwick DG, Kindrachuk RA, Redwine EA, Freiha FS, Stamey TA. Patterns of progression in prostate cancer. Lancet 1986; 1: 60-63.
10. Nowell P. The clonal evolution of tumor cell populations. Science 1976; 194: 23-28.
11. Peehl DM. Oncogenes in prostate cancer: An update. Cancer 1993; 71: 1159-1164.
12. Carter BS, Ewing CM, Ward WS et al. Allelic loss of chromo-somes 16q and 10q in human prostate cancer. Proc. Natl Acad. Sci. USA 1990; 87: 8751-8755.
13. Konishi N, Hiasa Y, Matsuda H et al. Intratumor heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma. Am. J. Pathol. 1995; 147: 1112-1122.
14. Carter BS, Epstein JI, Isaacs WB. ras gene mutations in human prostate cancer. Cancer Res. 1990; 50: 6830-6832.
15. Gumerlock PH, Poonamellee DR, Meyers FJ, deVere White RW. Activated ras alleles in human carcinoma of the prostate are rare. Cancer Res. 1991; 51: 1632-1637.
16. Konishi N, Enomoto T, Buzard G, Ohshima M, Ward JM, Rice JM. K-ras activation and ras p21 expression in latent prostatic carcinoma in Japanese men. Cancer 1992; 69: 2293-2299.
17. Anwar K, Nakakuki K, Shiraishi T, Naiki H, Yatani R, Inuzaka M. Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas. Cancer Res. 1992; 52: 5991-5996.
18. Suzuki H, Aida S, Akimoto S, Igarashi T, Yatani R, Shimazaki J. State of adenomatous polyposis coli gene and ras oncogenes in Japanese prostate cancer. Jpn J. Cancer Res. 1994; 85: 847-852.
19. Watanabe M, Shiraishi T, Yatani R, Nomura AMY, Stemmerman GN. International comparison on ras gene mutations in latent prostate carcinoma. Int. J. Cancer 1994; 58: 174-178.
20. Konishi N, Hiasa Y, Tsuzuki T, Tao M, Enomoto T, Miller MJ. Comparison of ras activation in prostate carcinoma in Japanese and American men. Prostate 1997; 30: 53-57.
21. Fleming WH, Hamel A, MacDonald R et al. Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia. Cancer Res. 1986; 46: 1526-1531.
22. Buttyan R, Sawchuk IS, Benson MC, Siegal JD, Olsson CA. Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers. Prostate 1987; 11: 327-337.
23. Eaton CL, Davies P, Phillips MEA. Growth factor involvement and oncogene expression in prostatic tumors. J. Steroid Biochem. 1988; 30: 341-345.
24. Gleave ME, Hsieh JT, von Eschenbach AC, Chung LWK. Prostate and bone fibroblasts induce human prostate cancer growth In vivo: Implication for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis. J. Urol. 1992; 147: 1151-1159.
25. Wagner AJ, Small MB, Hay N. Myc-mediated apoptosis is blocked by ectopic expression of Bcl-2. Mol. Cell. Biol. 1993; 13: 2432-2440.
26. Spencer CA, Groudine M. Control of c-myc regulation in normal and neoplastic cells. Adv. Cancer Res. 1991; 56: 1-48.
27. Marcu KB, Bossone SA, Patel AJ. mycfunction and regulation. Annu. Rev. Biochem. 1992; 61: 809-860.
28. Thompson TC, Park SH, Timme TL et al. Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer. Oncogene 1995; 10: 869-879.
29. Fournier G, Latil A, Amet Y et al. Gene amplifications in advanced-stage human prostate cancer. Urol. Res. 1995; 22: 343-347.
30. Zhau HYE, Zhou J, Symmans WF et al. Transfected neu oncogene induces human prostate cancer metastasis. Prostate 1996; 28: 73-83.
31. Pisters LL, Troncoso P, Zhau HE, Li W, von Eschenbach AC, Chung LWK. C-met proto-oncogene expression in benign and malignant human prostate tissues. J. Urol. 1995; 154: 293-298.
32. Phillips MEA, Ferro MA, Smith PJB, Davies P. Intranuclear androgen receptor development and protooncogene expression in human diseased prostate. Urol. Int. 1987; 42: 115-119.
33. Funa K, Nordgren H, Nilsson S. In situ expression of mRNA for proto-oncogenes in benign prostatic hyperplasia and in prostate carcinoma. Scand. J. Urol. Nephrol. 1991; 25: 95-100.
34. Shen R, Su Z-Z, Olsson CA, Fisher PB. Identification of the human prostatic carcinoma oncogene PTI-1 by rapid expression cloning and differential RNA display. Proc. Natl Acad. Sci. USA 1995; 92: 6778-6782.
35. Sun Y, Lin J, Katz AE, Fisher PB. Human prostatic carcinoma oncogene PTI-1 is expressed in human tumor cell lines and prostate carcinoma patient blood sample. Cancer Res. 1997; 57: 18-23.
36. Rubin SJ, Hallahan DE, Ashman CR et al. Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes. J. Surg. Oncol. 1991; 46: 31-36.
37. Gumerlock PH, Chi S-G, Shi X-B et al. p53 abnormalities in primary prostate cancer: Single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. J. Natl Cancer Inst. 1997; 89: 66-71.
38. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res. 1993; 53: 3369-3373.
39. Navona NM, Troncoso P, Pisters LL et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J. Natl Cancer Inst. 1993; 85: 1657-1669.
40. Konishi N, Hiasa Y, Hayashi I et al. p53 mutations occur in clinical, but not latent, human prostate carcinoma. Jpn. J. Cancer Res. 1995; 86: 57-63.
41. Hollatein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
42. Watanabe M, Ushijima T, Kakiuchi H et al. p53 gene mutations in human prostate cancers in Japan: Different mutation spectra between Japan and Western countries. Jpn. J. Cancer Res. 1994; 85: 904-910.
43. Bookstein R, Shew JY, Chen PL, Scully P, Lee W-H. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 1990; 247: 712-715.
44. Bookstein R, Rio P, Madreperla SA et al. Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc. Natl Acad. Sci. USA 1990; 87: 7762-7766.
45. INK4B gene alterations with immunohistochemical studies in human prostate carcinomas. Int. J. Oncol. 1996; 8: 107-112.
46. Phillips SMA, Barton CM, Lee SJ et al. Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. Br. J. Cancer 1994; 70: 1252-1257.
47. Serrano M, Hannon GJ, Beach DB. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1994; 366: 704-707.
48. Konishi N, Hiasa Y, Tao M et al. Focal distribution of p16/CDKN2 gene mutations within individual prostate carcinomas. Int. J. Oncol. 1996; 8: 549-554.
49. Koyama A, Suzuki H, Aida S, Yatani R, Shimazaki J. Mutational analysis of CDKN2 (CDK4I/MTS1) gene in tissues and cell lines of human prostate cancer. Jpn. J. Cancer Res. 1995; 86: 622-625.
50. Gao X, Chen YQ, Wu N et al. Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. Oncogene 1995; 11: 1395-1398.
51. Bergerheim USR, Kunimi K, Collins VP, Ekman P. Deletion mapping of chromosome 8, 10, and 16 in human prostatic carcinoma. Genes Chromosomes Cancer 1991; 3: 215-220.
52. Suzuki H, Emi M, Komiya A et al. Localization of a tumor suppressor gene associated with progression of human prostate cancer within a 1.2 Mb region of 8p22-p21.3. Genes Chromosomes Cancer 1995; 13: 168-174.
53. Avery A, Sandberg A. Chromosomal abnormalities and related events in prostate cancer. Hum. Pathol. 1992; 23: 368-380.
54. Cooney KA, Wetzel JC, Consolino CM, Wonjo KJ. Identification and characterization of proximal 6q deletion in prostate cancer. Cancer Res. 1996; 56: 4150-4153.
55. Takahashi S, Shan AL, Ritland SR et al. Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression. Cancer Res. 1995; 55: 4114-4119.
56. Ichikawa T, Ichikawa Y, Dong T et al. Localization of metastasis suppressor gene(s) for prostatic cancer to the short arm of human chromosome 11. Cancer Res. 1992; 52: 3486-3490.
57. Cooney KA, Wetzel JC, Marajver SD, Macoska JA, Singleton TP, Wonjo KJ. District regions of allelic loss on 13q in prostate cancer. Cancer Res. 1996; 56: 1142-1145.
58. Gao X, Zacharek A, Salkowski A et al. Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer. Cancer Res. 1995; 55: 1002-1005.
59. Macoska JA, Powell IJ, Sakr W, Lane M-A. Loss of the 17p chromosomal region in a metastatic carcinoma of the prostate. J. Urol. 1992; 147: 1142-1146.
60. Cher ML, Ito T, Weidner N, Carroll PR, Jensen RH. Mapping of regions of physical deletion on chromosome 16q in prostate cancer cells by fluorescence in situ hybridization (FISH). J. Urol. 1995; 153: 249-254.
61. Cher ML, Bova GS, Moore DH et al. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotype. Cancer Res. 1996; 56: 3091-3102.
62. Visakorpi T, Kallioniemi AH, Syvänen A-C et al. Genomic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res. 1995; 55: 342-347.
63. Konishi N, Tao M, Nakamura M, Kitahori Y, Hiasa Y, Nagai H. Genomic alterations in human prostate carcinoma cell lines by two-dimensional gel analysis. Cell. Mol. Biol. 1996; 42: 1129-1135.
64. Konishi N, Hiasa Y, Nakamura M, Kitahori Y, Matsubara K, Nagai H. Different patterns of DNA alterations detected by restriction landmark genomic scanning in heterogeneous prostate carcinomas. Am. J. Pathol. 1997; 150: 305-314.
65. Ewing CM, Ru N, Morton RA et al. Chromosome 5 suppresses tumorigenicity of PC 3 prostate cancer cells: Correlation with re-expression of α-catenin and restoration of E-cadherin function. Cancer Res. 1995; 55: 4813-4817.
66. Watanabe M, Kakiuchi H, Kato H et al. APC gene mutations in human prostate cancer. Jpn. J. Clin. Oncol. 1996; 26: 77-81.
67. Rubinfeld B, Souza B, Albert I et al. Association of the APC gene product with β-catenin. Science 1993; 262: 1731-1734.
68. Veronese ML, Bullrich F, Negrini M, Croce CM. The t(6:16) (p21;q22) chromosome translocation in the LNCaP prostate carcinoma cell line results in a tpc/hpr fusion gene. Cancer Res. 1996; 56: 728-732.
69. Lundgren R, Mandahl N, Heim S, Limon J, Henrikson H, Mitelman F. Cytogenetic analysis of 57 primary prostatic adenocarcinoma. Genes Chromosomes Cancer 1992; 4: 16-24.
70. Zenklusen JC, Thompson JC, Troncoso P, Kagan J, Conti CJ. Loss of heterozygosity in human primary prostate carcinomas: A possible tumor suppressor gene at 7q31.1. Cancer Res. 1994; 54: 6370-6373.
71. Kagan J, Stein J, Babarian RJ et al. Homozygous deletions at 8p22 and 8p21 in prostate cancer implicate these regions as the sites for candidate tumor suppressor genes. Oncogene 1995; 11: 2121-2126.
72. Vocke C, Pozzatti RO, Bostwick DG et al. Analysis of 99 microdissected prostate carcinomas reveals high frequency of allelic loss on chromosome 8p12-21. Cancer Res. 1996; 56: 2411-2416.
73. Emmert-Buck MR, Vocke CD, Pozzatti RO et al. Allelic loss on chromosome 8p12-21 in microdissected prostate intraepithelial neoplasia (PIN). Cancer Res. 1995; 55: 2959-2962.
74. Bova GS, Carter BS, Bussemakers JE et al. Homozygous deletion and frequent loss of chromosome 8p22 loci in human prostate cancer. Cancer Res. 1993; 53: 3869-3873.
75. Murakami YS, Albertsen H, Brothman AR, Leach RJ, White RL. Suppression of the malignant phenotype of human prostate cancer cell line PPC-1 by introduction of normal fragments of human chromosome 10. Cancer Res. 1996; 56: 2157-2160.
76. Trybus TM, Burgess AC, Wonjo KJ, Glover TW, Macoska JA. Distinct areas of allelic loss on chromosomal regions 10p and 10q in human prostate cancer. Cancer Res. 1996; 56: 2263-2267.
77. Eagle LR, Yin X, Brothman AR, Williams BJ, Atkin NB, Prochownik EV. Mutation of the Mxi1 gene in prostate cancer. Nat. Genet. 1995; 9: 249-255.
78. Zervos SJ, Gyuris J, Brent R. Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites. Cell 1993; 72: 223-232.
79. Gray IC, Phillips SMA, Lee SJ, Neoptolemos JP, Weissenbach J, Spurr NK. Loss of the chromosomal region 10q23-25 in prostate cancer. Cancer Res. 1995; 55: 4800-4803.
80. Dong J-T, Lamb PW, Rinker-Schaeffer CW et al. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 1995; 268: 884-886.
81. Dong J-T, Suzuki H, Pin SS et al. Down regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequency involves gene mutation or allelic loss. Cancer Res. 1996; 56: 4387-4390.
82. Gao X, Friess H, Graber HU et al. KAI1 expression is up-regulated in early pancreatic cancer and decreased in the presence of metastases. Cancer Res. 1996; 56: 4876-4880.
83. Umbas R, Schalken JA, Aalders TW et al. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res. 1992; 52: 5104-5109.
84. Koyama K, Emi M, Nakamura Y. The cell adhesion regulator (CAR) gene, Taql and insertion/deletion polymorphisms, and regional assignment to the peritelomeric region of 16q by linkage analysis. Genomics 1993; 16: 264-265.
85. Ray R, Miller DM. Cloning and characterization of a human c-myc promoter-binding protein. Mol. Cell. Biol. 1991; 11: 2154-2161.
86. Gao X, Zacharek A, Grignon DJ et al. Localization of potential tumor suppressor loci to a <2 Mb region on chromosome 17q in human prostate cancer. Oncogene 1995; 11: 1241-1247.
87. Bevilacqua G, Sobel ME, Liotta LA, Steeg PS. Association of low nm23 RNA levels in human primary infiltrating ductal breast carcinomas with lymph node involvement and other histopathological indicators of high metastatic potential. Cancer Res. 1989; 49: 5185-5190.
88. Konishi N, Nakaoka S, Tsuzuku T et al. Expression of nm23-H1 and nm23-H2 proteins in prostate carcinoma. Jpn. J. Cancer Res. 1993; 84: 1050-1054.
89. Rinker-Schaeffer CW, Hawkins AL, Ru N et al. Differential suppression of mammary and prostate cancer metastasis by human chromosomes 17 and 11. Cancer Res. 1994; 54: 6249-6256.
90. Hatada I, Hayashizaki Y, Hirotsune S, Komatsubara H, Mukai T. A genomic scanning method for higher organism using restriction sites as landmarks. Proc. Natl Acad. Sci. USA 1991; 88: 9523-9527.
91. Hirotsune S, Hatada I, Komatsubara H et al. New approach for detection of amplification in cancer DNA using restriction landmark genomic scanning method. Cancer Res. 1992; 52: 3642-3647.
92. Nagai H, Ponglikitmongkol M, Mita E et al. Aberration of genomic DNA in association with human hepatocellular carcinomas detected by 2-dimensional gel analysis. Cancer Res. 1994; 54: 1545-1550.
93. Yoshikawa H, DeLaMonte S, Nagai H, Wands JR, Matsubara K, Fujiyama A. Chromosomal assignment of human genomic Not restriction fragments in a two-dimensional electrophoresis profile. Genomics 1996; 31: 28-35.
94. Konishi N, Hiasa Y, Matsuda H, Nakamura M, Kitahori Y. Genetic variations in human benign prostatic hyperplasia detected by restriction landmark genomic scanning. J. Urol. 1997; 157: 1499-1503.
95. Evans BAJ, Harper ME, Daniells CE et al. Low incidence of androgen receptor gene mutations in human prostatic tumors using single strand conformation polymorphism analysis. Prostate 1996; 28: 162-171.
96. Koivisto P, Kononen J, Palmberg C et al. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 1997; 57: 314-319.
97. Taplin M-E, Bubley GJ, Shuster TD et al. Mutation of the androgen-receptorgene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 1995; 332: 1393-1398.
98. Gao X, Wu N, Grignon D et al. High frequency of mutator phenotype in human prostatic adenocarcinoma. Oncogene 1994; 9: 2999-3003.
99. Fishel R, Lescoe MK, Rao MRS et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993; 75: 1027-1038.
100. Bronner CE, Baker SM, Morrison PT et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 1994; 368: 258-261.
101. Watanabe M, Imai H, Shiraishi T, Shimazaki J, Kotake T, Yatani R. Microsatellite instability in human prostate cancer. Br. J. Cancer 1995; 72: 562-564.
102. Egawa S, Uchida T, Suyama K et al. Genomic instability of microsatellite repeats in prostate cancer: Relationship to clinocopathological variables. Cancer Res. 1995; 55: 2418-2421.
103. Suzuki H, Komiya A, Aida S et al. Microsatellite instability and other molecular abnormalities in human prostate cancer. Jpn. J. Cancer Res. 1995; 86: 956-961.
104. Watanabe M, Imai H, Kato H et al. Microsatellite instability in latent prostate cancers. Int. J. Cancer 1996; 69: 394-397.
105. Irvine RA, Yu MC, Ross RK, Coetzee GA. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res. 1995; 55: 1937-1940.
106. Counter CM, Avilion AA, LeFeuvre CE et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 1992; 11: 1921-1929.
107. Sommerfeld H-J, Meeker AK, Piatyszek MA, Bova GS, Shay JW, Coffey DS. Telomerase activity: A prevalent marker of malignant human prostate tissue. Cancer Res. 1996; 56: 218-222.
108. Kim NW, Piatyszek MA, Prowse KR et al. Specific association of human telomerase activity with immortalized cells and cancer. Science 1994; 266: 2011-2015.
109. Bird AP. CpG-rich islands and the function of DNA methylation. Nature 1986; 321: 209-213.
110. Sakai T, Toguchida J, Ohtani N, Yandell DW, Rapaport JM, Dryja TP. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am. J. Hum. Genet. 1991; 48: 880-888.
111. Herman JG, Latif F, Weng Y et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl Acad. Sci. USA 1994; 91: 9700-9704.
112. Herman JG, Merlo A, Mao L et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995; 55: 4525-4530.
113. INK4B1. Cancer Res. 1996; 56: 722-727.
114. Nelson JB, Lee W-H, Nguyen SH et al. Methylation of the 5′ CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res. 1997; 57: 35-37.
115. Vachtenheim J, Horáková I, Novotná H. Hypomethylation of CCGG sites in the 3′ region of H-ras protooncogene is fragment and is associated with H-ras allele in non-small cell lung cancer. Cancer Res. 1994; 54: 1145-1148.
116. Bedford M, van Helden PD. Hypomethylation of DNA in pathological condition of the human prostate. Cancer Res. 1987; 47: 5274-5276.
117. Krizman DB, Chuaqui RF, Meltzer PS et al. Construction of a representative cDNA library from prostatic intraepithelial neoplasia. Cancer Res. 1996; 56: 5380-5383.